Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Union Health Minister JP Nadda was admitted to AIIMS Delhi after experiencing uneasiness and underwent tests, including a coronary angiography. The hospital, in a statement, said he is stable and under observation in the cardiology department.

JP Nadda Under Observation

The 65-year-old minister was admitted on August 13 after experiencing uneasiness. He underwent tests, including coronary angiography.

“JP Nadda, Minister of Health and Family Welfare, was evaluated for uneasiness with tests including a coronary angiography on the evening of 13th August 2026. He is currently stable and admitted for observation in the Dept of Cardiology,” AIIMS said in a statement.

Is Uneasiness A Sign Of Heart Problems?

Heart problems do not always cause obvious symptoms. While common symptoms include chest pain or pressure, palpitations, and breathing difficulties, reduced blood flow to the heart can sometimes present with subtle signs or no symptoms.

Possible warning signs include:

• Unusual fatigue
• Shortness of breath
• Jaw pain
• Irregular heartbeat
• Swollen feet and ankles
• Dizziness
• Cough
• Leg pain or cramps
• Poor sleep

What Is Coronary Angiography?

Coronary angiography is a test used to check the blood vessels supplying the heart for narrowing or blockages.

A thin catheter is usually inserted through an artery in the wrist or groin. Contrast dye is injected, and X-rays are used to visualize the coronary arteries.

Why Is It Done?

Doctors may recommend coronary angiography for:

• Unexplained chest pain
• Abnormal results from tests such as an ECG, stress test or echocardiogram
• A heart attack, to locate a blocked artery
• Unexplained heart failure or cardiac arrest
• Certain congenital heart conditions

Why Are Heart Checkups Important?

Regular checkups can help detect heart disease early and monitor risk factors such as:

• Blood pressure
• Cholesterol
• Blood sugar

Who Should Consider Regular Heart Checkups?

Regular monitoring can help detect changes early and support timely action to reduce long-term cardiovascular risk.

Regular heart checkups are particularly important for people who:

• Are above 30
• Have a family history of heart disease
• Have high blood pressure, diabetes or high cholesterol
• Smoke or frequently consume alcohol
• Lead a sedentary lifestyle
• Are overweight or obese
• Experience ongoing stress

Common Tests Included In A Heart Checkup

Depending on individual risk factors, a heart checkup may include:

• Blood pressure measurement
• Blood tests for cholesterol, triglycerides and blood sugar
• ECG to assess heart rhythm
• Echocardiography to assess heart structure and function
• TMT or stress test to assess the heart during exertion

Additional tests, such as CT coronary angiography or specialized cardiac biomarkers, may be recommended in some cases.

Sixty-two deaths in Australia have been reported to the medicines regulator, the Therapeutic Goods Administration (TGA), with suspected associations with GLP-1 medicines, including Ozempic, Wegovy and Mounjaro.

The TGA has also received reports of nearly 3,000 serious adverse events involving these medicines, which are used by hundreds of thousands of Australians, The Herald Sun reported.

Reported adverse reactions include nausea, pancreatitis, suicidal thoughts and a rare eye condition that can cause blindness.

62 Death Reports Involving GLP-1 Medicines

Semaglutide, the active ingredient in Ozempic, used for type 2 diabetes, and Wegovy, approved for weight management, had the highest number of reported deaths with suspected associations.

Other medicines with reported suspected associations include Mounjaro (tirzepatide), Saxenda (liraglutide) and Trulicity (dulaglutide). These drugs are approved to treat type 2 diabetes, obesity, or both.

The reported deaths included:

• Semaglutide — 37 reports
• Tirzepatide — 9 reports
• Liraglutide — 11 reports
• Dulaglutide — 5 reports

The TGA states that adverse-event reports alone cannot determine how common a reaction is or be used to directly compare the safety of different medicines. The regulator also said the benefit-risk profile of these medicines remains positive when they are appropriately used for approved indications and in intended patients.

GLP-1 Drugs Carry New Warning For Rare Eye Condition

The TGA recently updated warnings for some GLP-1 medicines concerning non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but serious eye condition.

Product warnings across the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class have been updated because of the potential association with the disorder.

NAION can cause permanent visual impairment, including blindness. The TGA notes that no treatment has been shown to improve visual acuity outcomes in people who develop the condition.

GLP-1 RA medicines are prescription drugs used primarily to manage type 2 diabetes and obesity. Thus, the TGA urged patients not to stop treatment on their own.

“These are prescription medicines, so people taking them should discuss benefits, risks and side effects with their healthcare professional rather than stopping or changing treatment based on headlines alone,” the TGA said.

Death Reports From Other Countries

The Australian reports come amid safety monitoring of GLP-1 medicines in other countries. At the same time, clinical evidence has shown important health benefits from some GLP-1 medicines, including reductions in cardiovascular risk and, in certain populations, overall mortality.

Data submitted to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) showed 82 reported deaths associated with GLP-1 receptor agonists up to January 31, 2025. Of these, 22 were associated with use for weight loss and 60 with use for type 2 diabetes.

In the US, reports in the FDA's FAERS (FDA Adverse Event Reporting System) database have listed 162 deaths associated with Ozempic and Wegovy since 2018.

However, these figures should not be interpreted as confirmed deaths caused by the medicines. Adverse-event reporting systems record suspected associations and cannot by themselves establish a direct causal relationship. Millions of people use GLP-1 medicines, and reported cases can involve other health conditions or factors, including severe complications, dosing errors, and counterfeit or compounded products.

English singer-songwriter Robbie Williams has opened up about being diagnosed with “a little bit of autism” and shared his struggles with intrusive thoughts.

The 52-year-old singer revealed that he had earlier been diagnosed with ADHD, as well as Tourette’s syndrome, the Daily Mail reported.

Robbie Williams' Autism Diagnosis

Speaking at the launch of his clothing brand Hopeium at Flannels, Williams said his autism diagnosis has helped explain some of his behaviors.

“I have ADHD and I just found out I have a bit of autism as well, which I actually f*****g love because it explains so much,” he said.

The British pop icon said he now sees the diagnosis as an explanation for “all the weird” things he does. He also described how ADHD affects his ability to concentrate.

“With the ADHD you can completely and utterly concentrate on something 1000 per cent, but with absolutely everything else, you just cannot do it. Ask my kids,” he said.

The singer said he is “completely and utterly obsessed with creating images and making funny things”.

'My Brain Is Incredibly Creative'

Williams, who has won a record 18 BRIT Awards, said creativity helps him redirect his thoughts and avoid focusing on things that make him panic or feel scared.

“My brain is incredibly creative, and it can be creative about everything in the world that you panic or are scared about,” he said.

He gave the example of sitting on a plane and having an intrusive thought about possessing telekinetic powers and causing the plane to crash.

He said he has learned to “train my brain to do something better” rather than focusing on worrying thoughts.

What Is Autism?

Autism is a neurodevelopmental condition that can affect communication, social interaction and behavior. It is a spectrum, meaning symptoms and their severity can vary widely between individuals.

Common characteristics can include repetitive behaviors or interests, difficulty with changes in routine and challenges in social situations.

Robbie Williams on Tourette's Syndrome

Williams has also previously spoken about being diagnosed with Tourette’s syndrome. In a recent podcast, he said he had realized that some of the intrusive thoughts he experiences may be connected to Tourette’s, although he does not experience the typical outward tics.

“I've just realized that I have Tourette's, but they don't come out. They are intrusive thoughts that happen,” Williams said.

He also spoke about struggling to fully take in the reaction of audiences, despite performing in front of large crowds.

Williams Diagnosed With ADHD Thrice

Williams has said he was diagnosed with ADHD three times because he “forgot” that he had previously been told he had the condition. He first recalled being diagnosed around 2006 after recognizing ADHD symptoms while reading about the condition online.

After his diagnosis, he said he began taking a large number of tablets in the hope that they would “fix” him. He later said his substance misuse escalated, including crushing and snorting the pills.

Williams has faced several addictions and has had multiple stays in rehabilitation since rising to fame in the early 1990s.

What Is ADHD?

ADHD is a neurodevelopmental condition that can involve persistent difficulties with attention, organization and impulse control.

Symptoms can include being easily distracted, forgetfulness, losing things and difficulty maintaining concentration. Some people may also experience restlessness and impulsive behavior.